{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Year-End NERA Report Shows COVID-19-Related Federal Securities Litigation Disproportionately Targeting Life Sciences Firms",
    "url": "https://www.lexblog.com/2021/02/01/year-end-nera-report-shows-covid-19-related-federal-securities-litigation-disproportionately-targeting-life-sciences-firms/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-1DC8CX16",
        "url": "https://www.lexblog.com/lib/1DC8CX16/"
    },
    "datePublished": "2021-02-01T16:22:11-05:00",
    "dateModified": "2021-10-26T11:13:51-04:00",
    "author": {
        "@type": "Person",
        "name": "Gregg Weiner, Adam Harris, Life Sciences Litigation & Enforcement Team"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Ropes & Gray"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Life Sciences Securities Litigation",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.lifescienceslitigation.com/?p=2070",
    "sourceStability": "may-move"
}